Clinical trials: First Line Treatment
HIV-1 Infection
ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy
This is a non-inferiority (10% non-inferiority margin), study to assess the efficacy and safety of dolutegravir, DTG (50 mg once daily [QD]) administered in combination with tenofovir alafenamide fumarate, TAF (25 mg QD) and…
- Trial name
- ADVANCE (NCT03122262)
- Testing
- Dolutegravir, Tenofovir Alafenamide, Truvada
- Where
- 4 sites in South Africa
- Volunteers
- 1,110 people
- Sponsor
- Professor Francois Venter
Kawasaki Disease
Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
The purpose of this study is to determine whether the addition of infliximab to standard primary therapy of intravenous immunoglobulin (IVIG) and high dose aspirin will reduce resistance to therapy in acute Kawasaki disease (KD).
- Trial name
- NCT00760435
- Testing
- Infliximab
- Where
- 2 sites in United States
- Volunteers
- 196 people
- Sponsor
- University of California, San Diego
Brain and Central Nervous System Tumors
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give…
- Trial name
- NCT00008008
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Graft Versus Host Disease, GVHD
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
- Conditions
- Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD
- Trial name
- NCT05263999
- Testing
- Itolizumab
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 158 people
- Sponsor
- Equillium
Helicobacter Infections
Eradication Rates of Helicobacter Pylori and Its Affecting Factors
The purpose of this study is to investigate the trend of eradication rates of first-line triple therapy for Helicobacter pylori in recent ten years and clinical factors that affect the eradication in Korean.
- Trial name
- NCT01922505
- Testing
- PPI triple therapy
- Where
- South Korea
- Volunteers
- 2,500 people
- Sponsor
- Seoul National University Bundang Hospital
Phimosis
Mild Versus Potent Corticosteroids as Treatment for Phimosis in Children
Topical steroids are used as treatment for non-retractile foreskin in children for decades, but, there are disagreement among physicians about the optimum potency of the agent used.
- Trial name
- TopSteP (NCT00933023)
- Testing
- hydrocortisone, Betamethasone
- Where
- United Kingdom
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
Preterm Infants
NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)
The investigators compared advantages and disadvantages of two forms of noninvasive respiratory support -noninvasive high-frequency oscillatory ventilation (nHFOV) or nasal continuous positive airway pressure (nCPAP) -as a…
- Trial name
- NCT03099694
- Testing
- noninvasive high-frequency ventilation (nHFOV), nasal continuous positive airway pressure (nCPAP)
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Xingwang Zhu
Paediatric Hydrocephalus
Efficacy of Combined Endoscopic Third Ventriculostomy and Choroid Plexus Cauterization in Treatment of Hydrocephalus
Hydrocephalus remains one of the most common conditions encountered in neurosurgery, traditionally managed by ventriculoperitoneal (VP) shunting.
- Trial name
- NCT07735936
- Testing
- Combined endoscopic third ventriculostomy & coroid plexus cauterization
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Assiut University
Neonatal Seizures
Levetiracetam Treatment of Neonatal Seizures
Current treatments for the brain damaging complication of neonatal seizures are unsatisfactory. A multi-centre Chinese clinical trials with the aim to using oral Levetiracetam to develop new treatment strategies for the treatment…
- Trial name
- NCT02550028
- Testing
- Oral levetiracetam, Intravenous phenobarbital
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Steroid-refractory Acute Graft-versus-host Disease
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or…
- Trial name
- BALDER (NCT06075706)
- Testing
- MC0518, BAT
- Where
- 36 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- medac GmbH
Bone Sarcoma, Osteosarcoma
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Randomized, non-comparative, multicentre exploratory phase II study. Two arms concerning patients with bone sarcoma after the first line therapy: in the first arm, patients will be treated with Regorafenib for a maximum of 12…
- Conditions
- Bone Sarcoma, Osteosarcoma, Ewing Sarcoma, Chondrosarcoma
- Trial name
- REGOSTA (NCT04055220)
- Testing
- Treatment by Regorafenib, Surveillance
- Where
- 16 sites in France
- Volunteers
- 168 people
- Sponsor
- Centre Leon Berard
Leukemia, Aplastic Anemia
Methadone as an Alternative Treatment for Children Underdoing HSCT
Mucositis is a normal side effect of stem cell transplant which happens as a result of chemotherapy being given prior to a new donor cell infusion (bone marrow transplant).
- Conditions
- Leukemia, Aplastic Anemia, Bone Marrow Failure Syndromes, SCID
- Trial name
- MATCH (NCT06940570)
- Testing
- PCA plus methadone (Experimental), PCA Alone (SOC)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Neonatal Seizures
Efficacy of Intravenous Levetiracetam in Neonatal Seizures
A new anticonvulsant, levetiracetam will be studied to treat seizures in newborn infants. Current treatments for the brain damaging complication of neonatal seizures are unsatisfactory.
- Trial name
- NEOLEV2 (NCT01720667)
- Testing
- Intravenous levetiracetam, Intravenous phenobarbital
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Richard H. Haas
Acute Myeloid Leukemia, First Line Therapy
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid…
- Trial name
- NCT06928376
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, "3+7"
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Chinese PLA General Hospital
Autologous Stem Cell Transplantation
Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.
Plerixafor has been intensively used in recent years for harvesting autologous stem cells from lymphoma and myeloma adult patients. Its use is indicated after failure to harvest with GCSF alone.
- Trial name
- GCSF (NCT02006225)
- Testing
- Plerixafor
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Acute Lymphoid Leukemia Relapse, Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia
The purpose of this study is to determine Maximum Tolerated Dosage (MTD), Dosage Limited Toxicities (DLT), and the Rate Phase 2 Dosage of clofarabine when used in combination with etoposide, asparaginase, mitoxantrone and…
- Trial name
- Vandevol (NCT01279096)
- Testing
- Clofarabine
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Lille
Acute GVH Disease
MTX and Steroid as First-line Therapy for aGVHD
The aim of the study is to identify the efficacy and safety of methotrexate (MTX) combined corticosteroid as first-line therapy for acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation…
- Trial name
- NCT04960644
- Testing
- MTX, Corticosteroid
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Peking University People's Hospital
Waldenstrom's Macroglobulinemia
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM.
- Trial name
- NCT00492050
- Testing
- Bortezomib, Rituximab, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular entities; BRCA-like and non-BRCA-like.
- Trial name
- Triple-B (NCT01898117)
- Testing
- Carbo/cyclo, Carbo/cyclo + atezolizumab, Paclitaxel
- Where
- 49 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- The Netherlands Cancer Institute